Autopsy report · NCT01009203
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
Cause of deathSlow enrollment
“High patient withdrawal rate”
Life of this trial
- Registered 1 month before it started.
- Ran for about 3 years before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 2 years 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- New Mexico Cancer Research Alliance
- Sponsor type
- University, hospital or other
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Erlotinib; Temsirolimus
- Participants
- 13
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Opioid Consumption After Hospital Discharge in Orthopedic Surgery
“Low patient retention rate” - An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
“Study was withdrawn prior to patient dosing based on a business decision.” - SMMART Adaptive Clinical Treatment (ACT) Trial
“Withdrawn due to a change in therapeutic interventions.” - The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
“The recruitment rate was very low (one screening failure and one early withdrawal patient)” - The Effects of Rimonabant, on Weight and Metabolic Risk Factors
“Withdrawn due to medication withdrawal from the EMEA”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.